SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Thursday, ...

Core Viewpoint - Boston Scientific Corporation will host a conference call to discuss its financial results and business highlights for the second quarter of 2025 on July 23, 2025 [1] Group 1: Financial Results Announcement - The conference call will take place at 8:00 a.m. ET and will be led by the CEO Mike Mahoney and CFO Jon Monson [1] - A news release with the financial results will be issued prior to the conference call on the same day [1] Group 2: Webcast Information - A live webcast and replay of the event will be available at the company's investor relations website [2] - The replay will be accessible approximately one hour after the event concludes [2] Group 3: Company Overview - Boston Scientific is a global leader in medical technology, focusing on innovative solutions that improve patient health [3] - The company has been advancing medical science for over 45 years, providing a wide range of devices and therapies for various complex diseases [3]

Core Insights - Dividend yield is a key metric for identifying dividend stocks, reflecting the amount of a company's dividend as a percentage of its stock price, which can fluctuate daily [1] - A strong balance sheet, indicated by a low debt-to-equity ratio, is essential for long-term dividend sustainability [2][3] Company Summaries Costco - Costco has a dividend yield of 0.53% with an annual dividend of $5.20 and a 22-year track record of dividend increases [5] - The company has delivered a total return of over 266% over the past five years, with a debt-to-equity ratio of 0.21%, indicating strong financial health [6] - Investors should focus on the 12.7% average dividend growth over the last three years rather than the current yield [7] Archer-Daniels-Midland (ADM) - ADM boasts a dividend yield of 3.86% with an annual dividend of $2.04 and a 53-year history of dividend increases [8] - The company's debt-to-equity ratio stands at 0.34%, suggesting a stable dividend outlook [8] - However, ADM's growth is closely tied to commodity prices, which are cyclical, making it less defensive compared to consumer staples [9] Medtronic - Medtronic has a dividend yield of 3.26% with an annual dividend of $2.84 and a 49-year history of dividend increases [11] - The company is well-positioned in the aging population market and in AI and machine learning, with a debt-to-equity ratio of around 0.53% [12][13] - Despite its potential, Medtronic is not currently highlighted as a top buy by analysts, indicating some caution among investors [14]

Automatic inclusion in the appropriate growth and value style indexesHINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition will be effective today when the U.S. equity markets open. “Inclusion in the Russell Microcap® Index marks another important milestone for Microbot Medical. It reflects the strong execution ...

Core Insights - Gentherm expands its partnership with DUOMED into France, enhancing patient temperature management technologies across Europe [1][2] - DUOMED will distribute Gentherm's full patient temperature management portfolio, including the Astopad and Vytil-branded systems [2] - The partnership aims to leverage DUOMED's strong presence and relationships in Europe to improve healthcare delivery [3][4] Company Overview - Gentherm is a global leader in thermal management and pneumatic comfort technologies, with a diverse product range in automotive and medical sectors [5] - In 2024, Gentherm reported annual sales of approximately $1.5 billion and secured $2.4 billion in new automotive business awards [5] - DUOMED, part of the Palex group, specializes in medical technology sales, consultancy, and support, focusing on high-quality solutions for healthcare professionals [6] Product Insights - The Astopad resistive warming system and Vytil-branded convective warming system are key offerings in the partnership [2] - Early feedback from French clinicians indicates a preference for Vytil blankets due to their superior quality compared to competitors [4] - Vytil products are recognized for their quality, safety, and value, with a focus on usability and innovation [7]

LIMERICK, Ireland, June 26, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQC: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a leading healthcare technology and diagnostics company (“the Company”) has signed a multi-year Master Services Agreement with Kneat. The Company, which is headquartered in the United States, employs over 50,000 people and manufactures in more than a dozen countries worldwide. This manufacturer of medical technolog ...

Core Viewpoint - Lifeward Ltd. has successfully closed a public offering of 4,000,000 ordinary shares and accompanying warrants, raising approximately $2.6 million in gross proceeds, which will be used for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering price was set at $0.65 per ordinary share and associated ordinary warrant, with the warrants having an exercise price of $0.65 and expiring five years from the issuance date [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. - The potential additional gross proceeds from the exercise of the ordinary warrants, if fully exercised, could amount to another $2.6 million [3]. Group 2: Company Overview - Lifeward Ltd. is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, focusing on rehabilitation and recovery [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, with a mission to drive innovation in the field of physical rehabilitation [6].

Core Insights - 3D Systems has achieved FDA approval for a 3D bioprinting solution for the regenerative repair of peripheral nerve damage, in collaboration with TISSIUM [1][4] - The newly developed device, COAPTIUM® CONNECT with TISSIUM Light, is a bioabsorbable, atraumatic, and sutureless solution for nerve repair, marking a significant milestone in the industry [1][4] - The global 3D bioprinting market is projected to grow from $1.3 billion in 2024 to $2.4 billion by 2029, indicating strong growth potential for the sector [3] Company Developments - 3D Systems has been a leader in bioprinting for nearly a decade, focusing on developing technologies for regenerative medicine and personalized healthcare [2][3] - The company has collaborated with United Therapeutics Corporation since 2017 to create an unlimited supply of human lungs for transplantation, showcasing its commitment to advancing medical solutions [2][3] - 3D Systems has produced over two million implants and instruments for more than 100 CE-marked and FDA-cleared devices, demonstrating its extensive experience in the medical device sector [3] Industry Impact - The collaboration with TISSIUM sets a new standard for high-resolution elastomeric 3D-printed medical implants, enhancing the capabilities of bioprinting technologies [4] - 3D Systems' innovations in bioprinting are expected to transform patient care by enabling the fabrication of living tissues and developing new therapeutics [5] - The advancements in 3D bioprinting are anticipated to accelerate the adoption of additive manufacturing in the medical field, contributing to improved healthcare delivery [4][5]

Core Viewpoint - Lifeward Ltd. has announced a public offering of 4,000,000 ordinary shares and accompanying warrants at a price of $0.65 per share, aiming to raise approximately $2.6 million for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering includes 4,000,000 ordinary shares and warrants to purchase an additional 4,000,000 shares at the same price of $0.65 [1]. - The ordinary warrants will be exercisable immediately and will expire five years from the issuance date [1]. - The expected gross proceeds from the offering are approximately $2.6 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [3]. Group 3: Regulatory Information - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 25, 2025 [4]. - A preliminary prospectus has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Lifeward Ltd. specializes in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [6]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [6].

Core Insights - Aclarion, Inc. has initiated the first patient enrollment in the CLARITY trial, which aims to evaluate the clinical and economic value of its Nociscan platform in spine surgery for chronic low back pain [1][6] Company Overview - Aclarion is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to enhance clinical treatments [5] - The company is focusing on the chronic low back pain market with Nociscan, the first evidence-supported SaaS platform designed to help physicians differentiate between painful and nonpainful discs in the lumbar spine [5] Trial Details - The CLARITY trial is a prospective, randomized multi-center study that will enroll 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain across multiple high-volume sites in the US [2] - The trial will randomize patients in a 1:1 ratio between surgeons who are blinded and unblinded to the Nociscan results, with the primary endpoint being the change in back pain measured on a 100mm VAS scale at 12 months compared to baseline [2][6] - The first patient was enrolled at the Texas Back Institute, which has a strong history in advancing spine care through clinical trial research [2][6] Market Context - Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide with degenerative spine disease and low back pain [3] - Aclarion's Nociscan solution aims to objectively quantify chemical biomarkers associated with disc pain, potentially leading to improved surgical outcomes [3][6]